Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102469 | 0.85 | CYP1A2 (0.36) | CYP1A2CYP2A6TSHRLMNAALDH1A1 | |
| SCHEMBL6149211 | 0.83 | TSHR (0.48) | CYP1A2CYP2A6TSHRLMNAALDH1A1 | |
| SCHEMBL910129 | 0.83 | CYP1A2 (0.35) | CYP1A2CYP2A6TSHRLMNAALDH1A1 | |
| SCHEMBL910072 | 0.83 | ALDH1A1 (0.41) | CYP1A2CYP2A6TSHRLMNAALDH1A1 | |
| SCHEMBL535572 | 0.83 | TAAR1 (0.41) | CYP1A2CYP2A6LMNAALDH1A1MEN1 | |
| SCHEMBL20237221 | 0.83 | C1R (0.35) | CYP1A2CYP2A6TSHRLMNAALDH1A1 | |
| SCHEMBL16634675 | 0.78 | ALDH1A1 (0.34) | CYP1A2CYP2A6LMNAALDH1A1MEN1 | |
| SCHEMBL9113536 | 0.78 | GRIA1 (0.42) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL909839 | 0.78 | SLC22A12 (0.44) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL16634611 | 0.76 | GRIA1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 549 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118159542-A | Substituted 2, 3-dihydro [1,3] thiazolo [4,5-b ] pyridines, salts thereof and their use as herbicidal agents | 拜耳公司 | 2024-06-07 | — | — | CN | claimed |
| CN-110678447-B | Modified nucleic acid monomer compounds and oligonucleotide analogues | 卫材R&D管理有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-107771178-B | Synthesis of heterocyclic compounds | 普莱希科公司 | 2021-04-06 | — | — | CN | claimed |
| EP-3298012-B1 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | PLEXXIKON INC (US) | 2020-09-02 | — | — | EP | claimed |
| EP-3275867-B1 | PYRIDO-FUSED BICYCLIC COMPOUNDS AS URAT1 INHIBITORS FOR TREATING HYPERURICEMIA | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-06-10 | — | — | EP | claimed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | claimed |
| CN-110669107-A | Antibacterial peptide and preparation method thereof | 上海医药工业研究院 | 2020-01-10 | — | — | CN | claimed |
| US-10100016-B2 | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2018-10-16 | — | — | US | claimed |
| US-20180265476-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2018-09-20 | — | — | US | claimed |
| CN-108516958-A | Fused-ring derivatives, preparation method, intermediate, pharmaceutical composition and application | 上海璎黎药业有限公司 | 2018-09-11 | — | — | CN | claimed |
| EP-0281186-B1 | PROCESS FOR THE PREPARATION OF A BENZOIC ACID DERIVATIVE | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1992-10-28 | — | — | EP | claimed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | claimed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| US-4801706-A | ANTIARRHYTHMIA HYPOTENSIVE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-01-31 | — | — | US | claimed |
| EP-0008880-B1 | 1-(2,6-DICHLOROBENZOYL)-3-(5-SUBSTITUTED-2-PYRIDINYL) UREAS, THEIR PREPARATION, FORMULATIONS AND USE AS INSECTICIDES | ELI LILLY AND COMPANY (US) | 1983-02-09 | — | — | EP | claimed |
| WO-1982001187-A1 | CNS STIMULANTS | AMERICAN HOME PROD (US) | 1982-04-15 | — | — | WO | claimed |
| EP-0049604-A1 | CNS stimulants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-04-14 | — | — | EP | claimed |
| US-4322429-A | Isoxazolylbenzamides as insecticides | ELI LILLY AND COMPANY (US) | 1982-03-30 | — | — | US | claimed |
| EP-0048162-A1 | Isoxazolylbenzamides | ELI LILLY AND COMPANY (US) | 1982-03-24 | — | — | EP | claimed |
| US-4301167-A | ANTIINFLAMMATORY AGENTS, ANALGESICS | INSTITUT MERIEUX (FR) | 1981-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265476-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | URB2, UGP2, NLRP3 | CYP1A2 524/4885CYP2A6 2479/4885TSHR 4189/4885 |
| US-10100016-B2 | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | URB2, UGP2, NLRP3 | CYP1A2 524/4885CYP2A6 2479/4885TSHR 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.